Program - Society of Toxicology

50 th Anniversary Annual Meeting and ToxExpo
Continuing Education (Continued)
CE
• Importance of Integrating Physicochemical Characterization
Information in Toxicity Assessment of Engineered Nanomaterials,
Scott McNeil, National Cancer Institute, Bethesda, MD
• Emergence of High Content Screening for Assessment of
Nanotoxicity, Chris Vulpe, University of California Berkeley,
Berkeley, CA
• Proteomic Profiling of the Biological Effects of Engineered
Nanomaterial Exposure Using In Vitro Models, Frank A. Witzmann,
Indiana University School of Medicine, Indianapolis, IN
• Correlating In Vitro and In Vivo Nanotoxicity: Limitations and
Challenges, Günter Oberdörster, University of Rochester Medical
Center, Rochester, NY
Sunday Afternoon, March 6
1:15 PM to 5:00 PM
First and Second Level (See signage at CE Booths for room
locations)
Toxicity Testing: State of Science and Strategies to
Improve Public Health
New Technologies and Approaches in Genetic Toxicology
and Their Expanding Role in General Toxicology and Safety
Assessment
PM11
CE Basic
Chairperson(s): Jeffrey C. Bemis, Litron Laboratories, Rochester, NY, and
Jennifer C. Sasaki, Johnson & Johnson, Raritan, NJ.
Sponsor:
Regulatory and Safety Evaluation Specialty Section
Endorsed by:
In Vitro and Alternative Methods Specialty Section
For decades, genetic toxicology and the “genetox battery” have been
a well-established part of safety testing for pharmaceuticals and other
chemical agents. Recent advances in experimental methodologies are
contributing to a change in the way that genetic toxicology data are
generated and incorporated in the disciplines of toxicology and safety
testing. The intention of this course is to illustrate the broader impact that
new genetic toxicology approaches are having on drug/chemicals safety
assessment and human risk analysis. The structure of the course will
provide examples of (1) Early discovery/high-throughput genotoxicity
screening of chemical entities; (2) Integration of genetic toxicology assays
with repeat-dose in vivo toxicology studies; and (3) New approaches for
genotoxicity risk assessment, and conclude with an update on genotoxic
impurity management strategies for pharmaceuticals. Speaker presentations
will illustrate how genotoxicity testing is evolving from a hazard
identification based-discipline to an integrated approach that may ultimately
yield quantitative information that can be used for human risk
assessment.
This course should be of interest to experienced genetic toxicologists as
well as those involved in general toxicology who want to learn about how
incorporation of new genotoxicity methods can improve test predictivity,
lower costs, reduce animal use, and may ultimately be applied to human
risk assessment
• Introduction, Jeffrey C Bemis, Litron Laboratories, Rochester, NY
• High-Throughput Genetic Toxicity Screening Assays in Discovery
Research & Development, Richard Walmsley, Gentronix, Ltd., and
The University of Manchester, United Kingdom
• The In Vitro Micronucleus Assay in Mammalian Cells: A High
Content Assay, Anthony M. Lynch, GlaxoSmithKline, Hertfordshire,
United Kingdom
• Genetic Toxicity and Thresholds: State of the Science, B. Bhaskar
Gollapudi, The Dow Chemical Company, Midland, MI
• Integration of Genetic Toxicology Endpoints into Repeat-Dose
Toxicity Studies, Maik Schuler, Pfizer PGRD, Groton, CT
• Risk Assessment of Genotoxic Impurities in Pharmaceuticals, Lutz
Mueller, Hoffmann La Roche, Inc., Basel, Switzerland
Sunday Afternoon, March 6
1:15 PM to 5:00 PM
First and Second Level (See signage at CE Booths for room
locations)
Epigenetic Mechanisms
Practical How-To and Pitfalls Associated with Current
Epigenetic Studies
PM12
CE Advanced
Chairperson(s): Reza John Rasoulpour, The Dow Chemical Company,
Midland, MI, and Chunhua Qin, Merck & Co., Inc., West Point, PA.
Sponsor:
Molecular Biology Specialty Section
The study of toxicant-induced epigenetic modifications is greatly
expanding in complexity and scope as new tools of measuring these
changes become available. Fundamental questions (e.g., how best to
quantify changes) become enigmatic with DNA methylation, histone
modifications, and microRNA epigenetic modifications that can affect
imprinted, coding, non-coding, and global regions of the genome.
Understanding these questions is important in interpreting species/
strain-specific responses. This advanced course is a practical guide to
techniques used in epigenetic research with respect to toxicology for
in vivo/ex vivo screening of rodent models, post-fertilization, embryos,
developmental biology, and human disease states. Topics range from
advancements in techniques to screening strategies and tools, and include
techniques to correlate epigenetic changes to gene expression and apical
end points, use of imprinted genes as biomarkers, and profiling DNA
methylation in human population-based research. For screening tools to
determine species-specific responses, a variety of novel technologies will
be analyzed such as epigenomic profiling of DNA methylation in mouse
tumors, pyrosequencing to examine the activity of endogenous retroviruses
(e.g., IAP), and assays to explore miRNA and histone modification
changes. In addition, cutting-edge techniques such as deep sequencing
technologies of bisulfite-converted DNA will be discussed as these have
enabled the characterization of methylation changes at the genome level;
however, the significant challenge in using this technology is dealing
with the massive amount of information obtained and making sense of
the observed methylation changes. Scientists in academia, industry, and
government will leave this course with an understanding of the strengths
and weaknesses of available epigenetic tools, how these tools can be best
used in screening and mode-of-action experiments, as well as insight into
future potential of mechanistic epigenetic toxicology.
• Screening Tools and Approaches for Methylation Analysis of
Imprinted Genes, Reza John Rasoulpour, The Dow Chemical
Company, Midland, MI
• Profiling Epigenetic Changes in Rodent Tumor Models, Chunhua
Qin, Merck & Co., Inc., West Point, PA
• Evaluating Epigenetic Changes in Germ Cells and Early Embryos,
Barbara F. Hales, McGill University, Montréal, Québec, Canada
94 SOT 50th Anniversary Annual Meeting